Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis

IMPORTANCE: Risk of nephrogenic systemic fibrosis (NSF) to individual patients with stage 4 or 5 chronic kidney disease (CKD; defined as estimated glomerular filtration rate of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of internal medicine (1960) 2020-02, Vol.180 (2), p.223-230
Hauptverfasser:	Woolen, Sean A, Shankar, Prasad R, Gagnier, Joel J, MacEachern, Mark P, Singer, Lisa, Davenport, Matthew S
Format:	Artikel
Sprache:	eng
Schlagworte:	Contraindications, Drug Contrast agents Contrast Media - adverse effects Gadolinium - adverse effects Glomerular Filtration Rate Heterocyclic Compounds - adverse effects Humans Kidney diseases Medical screening Meglumine - adverse effects Meglumine - analogs & derivatives Meta-analysis Nephrogenic Fibrosing Dermopathy - chemically induced Online First Organometallic Compounds - adverse effects Original Investigation Practice Guidelines as Topic Renal Insufficiency, Chronic - metabolism Risk Severity of Illness Index Systematic review United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	IMPORTANCE: Risk of nephrogenic systemic fibrosis (NSF) to individual patients with stage 4 or 5 chronic kidney disease (CKD; defined as estimated glomerular filtration rate of
ISSN:	2168-6106 2168-6114
DOI:	10.1001/jamainternmed.2019.5284